NCT05149209

Brief Summary

  • This study will be conducted to evaluate and compare the clinical performance of fluoride, calcium, and phosphate-releasing new bioactive material versus a fluoride-releasing hybrid restorative material in cervical lesions for one-year follow-up.
  • The clinical evaluation will be done using modified USPHS criteria at baseline,3,6,9 and 12 months.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 8, 2021

Completed
7 days until next milestone

Study Start

First participant enrolled

December 15, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2022

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

December 8, 2021

Status Verified

November 1, 2021

Enrollment Period

1 year

First QC Date

November 25, 2021

Last Update Submit

November 25, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Marginal adaptation

    The restoration will be clinically assessed by visual inspection and explorer. Restorations will be given a score using modified USPHS criteria: Alfa: Closely adapted, no visible crevice Bravo: Visible crevice, the explorer will penetrate Charlie: Crevice in which dentin is exposed

    one year

Secondary Outcomes (5)

  • Marginal Discoloration

    one year

  • Retention

    one year

  • Secondary caries

    one year

  • surface texture

    one year

  • postoperative sensitivity

    one year

Study Arms (2)

Fluoride, calcium and phosphate-releasing new bioactive material (Activa™ Presto, Pulpdent®, USA).

EXPERIMENTAL

ACTIVA Presto is a novel bioactive material with a mineral-enriched hydrophilic resin base and a patented rubberized component that resists abrasion and wear with high release and recharge of not only fluoride but also calcium and phosphate ions. It doesn't contain BIS-GMA, Bisphenol A, or BPA derivatives.

Procedure: cervical restoration

Fluoride-releasing hybrid restorative material (Giomer, Shofu, Japan).

ACTIVE COMPARATOR

Giomer is a hybrid restorative material that contains a resin base and pre-reacted glass ionomer. S-PRG (surface reaction type) technology provides some properties of GI such as fluoride release and recharge which helps prevent recurrent caries.

Procedure: cervical restoration

Interventions

A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.

Fluoride, calcium and phosphate-releasing new bioactive material (Activa™ Presto, Pulpdent®, USA).Fluoride-releasing hybrid restorative material (Giomer, Shofu, Japan).

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male or female gender.
  • Only co-operative patients will be approved to participate in the trial.
  • Medically free adult patients.
  • Small to moderate cervical lesion.
  • Vital upper or lower teeth with no signs of irreversible pulpitis.
  • Caries extension shouldn't exceed mesiodistal width and inciso(occluso)-gingival length not exceed incisal (occlusal) one third.

You may not qualify if:

  • Allergic history concerning methacrylates
  • Pregnancy
  • Heavy smoking; xerostomia
  • Lack of compliance
  • Patients with disabilities.
  • Patients having systemic diseases or severe medically compromised.
  • Patients with severe bruxism, clenching, or temporomandibular joint disorders.
  • Deep defects (close to the pulp, less than 1 mm distance).
  • Periapical pathology or signs of pulpal pathology.
  • Possible prosthodontic restoration of teeth.
  • Heavy occlusion and occlusal contacts or history of bruxism.
  • Pulpitis, non-vital or endodontically treated teeth.
  • Sever periodontal affection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nourhan Khaled Mohamed Samir

Cairo, Maadi, 11728, Egypt

Location

MeSH Terms

Conditions

Dental Caries

Condition Hierarchy (Ancestors)

Tooth DemineralizationTooth DiseasesStomatognathic Diseases

Central Study Contacts

Nourhan K Mohamed, B.D.S

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The participants will be blinded to the technique used since the patient will attend the same number of visits and he can not differentiate between different restorative materials. The operator cannot be blinded because of the difference in the application procedures of each restorative material. The outcome assessor will be blinded to the material used. This will be performed by M.S. and Y.H. Therefore the assessors mustn't be included in the preclinical assessment.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized Parallel Controlled Trial. Trial type: Two, Parallel arm design. Trial framework: Equivalence frame Allocation ratio: 1:1.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident at Conservative department

Study Record Dates

First Submitted

November 25, 2021

First Posted

December 8, 2021

Study Start

December 15, 2021

Primary Completion

December 15, 2022

Study Completion

December 30, 2022

Last Updated

December 8, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will share

* Full protocol will be published online in Clinicaltrials.gov to avoid repetition, and keep the integrity of the research work. * Thesis will be discussed and defended in front of a judging committee. * The study will be published to report the results of this clinical trial.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
24 months
Access Criteria
open access

Locations